发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy 罗氏许可Chiasma的晚期口腔肢端肥大症治疗
Pharmadeals Review Pub Date : 2013-02-26 DOI: 10.3833/PDR.V2013I2.1902
Heather Cartwright
{"title":"Roche Licenses Chiasma’s Late-Stage Oral Acromegaly Therapy","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I2.1902","DOIUrl":"https://doi.org/10.3833/PDR.V2013I2.1902","url":null,"abstract":"Roche has added a Phase III asset to its development pipeline by licensing global development and commercialisation rights to Israeli biotech Chiasma’s lead drug candidate Octreolin®, an oral form of the somatostatin analogue octreotide that is commercially available only by painful injection. Octreolin is in Phase III development for acromegaly and a Phase II study for neuroendocrine tumours is planned for 2013. The product is formulated using Chiasma’s TPE™ (Transient Permeability Enhancer) system, which facilitates the intestinal absorbance of drug molecules with limited intestinal bioavailability.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88621068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lycera and Merck & Co. Form Second Autoimmune Disease Collaboration 甘油三酯和默克公司形成第二自身免疫性疾病合作
Pharmadeals Review Pub Date : 2013-02-20 DOI: 10.3833/pdr.v2013i2.1900
Heather Cartwright
{"title":"Lycera and Merck & Co. Form Second Autoimmune Disease Collaboration","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i2.1900","DOIUrl":"https://doi.org/10.3833/pdr.v2013i2.1900","url":null,"abstract":"Merck & Co. and Lycera have partnered for a second time by forming a collaboration to discover, develop and commercialise small molecule therapies directed at multiple autoimmune disease targets. As part of the deal, which is potentially worth more than US$300 M to Lycera, Merck will be responsible for clinical development and will have global rights to products emerging from the collaboration. The two companies first partnered in March 2011 to develop drug candidates targeting T-helper 17 (Th17) cells and Lycera achieved its first milestone under the agreement in December 2011.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"569 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77266251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis 艾伯维将ii期抗体项目授权给嗜酸性食管炎受体
Pharmadeals Review Pub Date : 2013-02-04 DOI: 10.3833/PDR.V2013I4.1914
Heather Cartwright
{"title":"AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1914","DOIUrl":"https://doi.org/10.3833/PDR.V2013I4.1914","url":null,"abstract":"Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis. ABT-308, a humanised anti-interleukin-13 (IL-13) monoclonal antibody that has been designated RPC4046 by Receptos, was well tolerated in a Phase I study in healthy volunteers and patients with mild-to-moderate persistent asthma.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2013 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74231110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase 味之素收购Althea Technologies扩大生物制剂开发和制造能力
Pharmadeals Review Pub Date : 2013-01-04 DOI: 10.3833/pdr.v2013i4.1913
Heather Cartwright
{"title":"Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i4.1913","DOIUrl":"https://doi.org/10.3833/pdr.v2013i4.1913","url":null,"abstract":"Ajinomoto has agreed to acquire Althea Technologies, a US-based provider of biopharmaceutical development and manufacturing services, in a deal valued at approximately US$175 M. The Japanese company has been manufacturing amino acids for more than 100 years and in recent years has been offering contract process development for biopharmaceuticals. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that provides a means of formulating large molecules that must be delivered at high concentrations or as sustained-release formulations.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77176012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine 雀巢与和黄医药合资开发中药药物
Pharmadeals Review Pub Date : 2012-12-15 DOI: 10.3833/PDR.V2012I12.1861
Heather Cartwright
{"title":"Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I12.1861","DOIUrl":"https://doi.org/10.3833/PDR.V2012I12.1861","url":null,"abstract":"Nestle Health Science and Hutchison China MediTech (Chi-Med) have formed a 50-50 joint venture (JV) for the research, development, manufacturing and commercialisation of medicines and nutritional products derived from botanical extracts. The JV, to be named Nutrition Science Partners, will initially focus on gastrointestinal diseases and may subsequently expand into metabolic diseases and brain health. It will also assume responsibility for the development of Chi-Med’s HMPL-004, an oral therapy for inflammatory bowel disease that is derived from a botanical extract and which is scheduled to begin Phase III trials in early 2013.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82648238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition smith&nephew收购Healthpoint生物疗法，进入快速增长的生物活性伤口护理领域
Pharmadeals Review Pub Date : 2012-12-13 DOI: 10.3833/pdr.v2012i12.1860
Heather Cartwright
{"title":"Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i12.1860","DOIUrl":"https://doi.org/10.3833/pdr.v2012i12.1860","url":null,"abstract":"In order to move into the fast-growing bioactive wound care market, Smith & Nephew (S&N) has agreed to acquire substantially all the assets of Healthpoint Biotherapeutics for US$782 M in cash. A key driver of the deal is Collagenase Santyl®, the only US FDA approved enzymatic debrider that S&N itself used to market. The company will also gain strong commercial capabilities in the US and a pipeline led by HP802-247, which is in Phase III development for venous leg ulcers and offers significant upside potential.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83213217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal Avanir授权Concert的氘修饰右美沙芬产品，潜在交易价值2亿美元
Pharmadeals Review Pub Date : 2012-12-03 DOI: 10.3833/pdr.v2012i3.1696
Heather Cartwright
{"title":"Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i3.1696","DOIUrl":"https://doi.org/10.3833/pdr.v2012i3.1696","url":null,"abstract":"In a deal that could be worth more than US$200 M, Avanir Pharmaceuticals has licensed global rights to Concert Pharmaceuticals’ multiple deuterium-modified dextromethorphan (d-DM) products for the potential treatment of neurological and psychiatric disorders. Avanir’s sole marketed product is Nuedexta® (dextromethorphan plus quinidine sulphate), which was approved by the US FDA in 2010 for pseudobulbar affect.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78434478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition Pernix Therapeutics通过收购Cypress Pharmaceutical扩大了仿制药和品牌产品组合
Pharmadeals Review Pub Date : 2012-11-26 DOI: 10.3833/PDR.V2012I11.1840
Heather Cartwright
{"title":"Pernix Therapeutics Expands Generic and Branded Product Portfolios with Cypress Pharmaceutical Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I11.1840","DOIUrl":"https://doi.org/10.3833/PDR.V2012I11.1840","url":null,"abstract":"Pernix Therapeutics, a US-based speciality pharmaceutical company primarily focused on the paediatric market, has agreed to acquire the privately held generics developer Cypress Pharmaceutical and its branded pharmaceuticals subsidiary Hawthorn Pharmaceuticals for up to US$101 M in cash and stock. Cypress and Hawthorn are together expected to generate revenues of approximately US$50 M in 2012. The acquisition is Pernix’s second of 2012 after its July purchase of Great Southern Laboratories, a contract manufacturer of OTC and prescription products.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77912824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme 罗氏授权Galaxy Biotech的临床前FGF2抗体项目
Pharmadeals Review Pub Date : 2012-11-10 DOI: 10.3833/PDR.V2012I10.1818
Heather Cartwright
{"title":"Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I10.1818","DOIUrl":"https://doi.org/10.3833/PDR.V2012I10.1818","url":null,"abstract":"Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis. Roche will assume responsibility for the development and commercialisation of the programme and will pay Galaxy US$8 M upfront as well as potential milestone payments and royalties. The deal comes 3 months after Takeda Pharmaceutical terminated its licence agreement with Galaxy for the anti-HGF (hepatocyte growth factor) monoclonal antibody HuL2G7.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"238 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77377366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout Valeant以26亿美元收购Medicis，引领美国皮肤科市场
Pharmadeals Review Pub Date : 2012-11-09 DOI: 10.3833/PDR.V2012I9.1803
Heather Cartwright
{"title":"Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1803","DOIUrl":"https://doi.org/10.3833/PDR.V2012I9.1803","url":null,"abstract":"Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash. The offer price represents a 39% premium to Medicis’ closing price prior to the announcement of the transaction and values Medicis at approximately US$2.6 B. With the acquisition, Valeant will become the leading player in the US dermatology market.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78200126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信